VVelarionINTELLIGENCE
Sign inStart free trial
Start free trial
Biopharma & Life Sciences

Prime Medicine Executive Compensation (FY25)

PRME · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025
◇
Allan Reine
Velarion Intel, $5,000/year: one seat · one year · every company we cover, with dashboards, peer screens and board-ready briefs.
See every company’s exec pay — free for 3 days, no cardSee the plan and pricing

The Prime Medicine brief, $500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $500 for the board report; $900 for both.
Get the executive briefGet the board briefNo account needed.
Data as of November 6, 2026Latest filing (DEF 14A): April 23, 2026
3 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Prime Medicine brief$500Get the executive brief
Velarion Intel, one year, every company
161 figures on this page, cited to the filing that reported them. See the citations
This company is not required to report a chief executive pay ratio.
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Allan Reine: $4,623,802 → $3,894,187 (15.8% lower)

Frequently asked questions

Answers drawn from the data on this page.
Who is Prime Medicine's chief executive and what were they paid?
Total compensation for Allan Reine, Chief Executive Officer, came to $3,894,187 in fiscal 2025. Compared with the $4,623,802 reported for fiscal 2024, Reine's total was 15.8% lower.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Ann Lee
Chief Technical Officer
◇———◇—◇◇
Keith Gottesdiener
President & Chief Executive Officer
◇———◇—◇◇
Jeremy FRCP
Chief Scientific Officer
◇———◇—◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Keith Gottesdiener
President & Chief Executive Officer
◇——◇◇—◇◇
Ann Lee
Chief Technical Officer
◇——◇◇—◇◇
Jeremy FRCP
Chief Scientific Officer
◇——◇◇—◇◇
Jeremy Duffield
Chief Scientific Officer
◇——◇◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Allan Reine
Chief Financial Officer
◇◇—◇◇—◇◇
Keith Gottesdiener
President & Chief Executive Officer
◇——◇◇—◇◇
Jeremy Duffield
Chief Scientific Officer
◇——◇◇—◇◇
Jeremy FRCP
Former Chief Scientific Officer
◇——◇◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Allan Reine
Chief Executive Officer
◇——◇◇—◇◇
Keith Gottesdiener
Former Chief Executive Officer
Departed during or after this year
◇——◇——◇◇
Ann Lee
Chief Technical Officer
◇——◇◇—◇◇
Jeremy Duffield
Former Chief Scientific Officer
Departed during or after this year
◇——◇——◇◇
Jeremy FRCP
Former Chief Scientific Officer
Departed during or after this year
◇——◇——◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Allan Reine, M.D.OPTION◇——◇——◇
Allan Reine, M.D.OPTION◇——◇——◇
Allan Reine, M.D.OPTION◇——◇——◇
Ann LeeOPTION◇——◇—◇◇
Ann LeeOPTION◇——◇—◇◇
Ann LeeOPTION◇——◇—◇◇
Jeremy DuffieldOPTION◇————◇◇
Jeremy Duffield FRCPOPTION◇——◇—◇◇
Keith GottesdienerOPTION◇——◇—◇◇
Fiscal 2023, 2024 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Allan ReineOption◇—◇05/19/2035
Option◇—◇01/17/2034
Option◇—◇02/27/2035
Keith GottesdienerOption◇—◇02/28/2035
Option◇—◇03/31/2033
Option◇—◇02/25/2034
Jeremy DuffieldOption◇—◇02/27/2035
Option◇—◇02/21/2034
Option◇—◇03/31/2033
Ann LeeOption◇—◇02/27/2035
Option◇—◇02/21/2034
Option◇—◇03/31/2033
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Jeffrey D. Marrazzo
Board chair
◇—◇——◇◇
Michael Kelly
◇—◇———◇
Kaye Foster
◇—◇———◇
Wendy Chung, M.D., Ph.D
◇—◇———◇
David Schenkein, M.D
◇—◇———◇
Thomas Cahill, M.D., Ph.D
◇—◇———◇
Robert Nelsen
◇—◇———◇
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board chair premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇
Equity is delivered as Options.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Allan Reine (Chief Executive Officer), FY2025 total compensation $3,894,187 (base salary $606,212) [exec_comp, SEC accession 0001628280-26-026697, filed 2026-04-23]

See a complete sample report

Answered within 24 hours, every figure cited to its SEC filing. This is a one-off report: no refunds.

Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Prime Medicine files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Prime Medicine disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $500
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether Prime Medicine's disclosed peer group is defensible, who names Prime Medicine back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
161 figures on this page, cited to the filing that reported them.
161 cited to the filing

Documents cited

  1. 0001628280-26-026697
    M.D.
  2. 0001628280-25-018704
  3. 0001628280-24-018977
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Prime Medicine executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/PRME (accessed 2026).
Short form: data: Velarion

The Prime Medicine brief, $500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $500 for the board report; $900 for both.
Get the executive briefGet the board briefNo account needed.
3 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Prime Medicine and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy